{
  "name": "EQL Pharma",
  "slug": "eql-pharma",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T03:29:50Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 21.70, volym 36574",
  "mfn_status": "retrieved",
  "mfn_count": 1,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/eql-pharma/reports",
    "count": 11,
    "nasdaq_count": 10,
    "mfn_fallback_count": 1,
    "items": [
      {
        "report_key": "2026:annual",
        "period_label": "2026 Årsredovisning",
        "date": "2026-07-24",
        "title": "Årsredovisning 2026",
        "original_title": "EQL Pharma Årsredovisning 2025/2026",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bce76992aa38bcf12986ce27193ba94fa&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2026,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2026",
            "title": "Årsredovisning 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a76a4c5117e3991ffc7424168f48001fe",
            "date": "2026-07-24",
            "period": "2026-annual",
            "form_type": "annual-report",
            "report_key": "2026:annual",
            "filename": "07231483.pdf",
            "text_chars": 270184,
            "sha256": "703dc9cf331cb86c3e871eef359c8c9e1f350bd66693297339ebc43f54cfbb50",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/part-001.html",
                "chars": 177508
              },
              {
                "number": 2,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/part-002.html",
                "chars": 92674
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2026:q4",
        "period_label": "2026 Q4",
        "date": "2026-05-08",
        "title": "Kvartalsrapport Q4 2026",
        "original_title": "Bokslutskommuniké april 2025 - mars 2026",
        "category": "year-end-report",
        "source": "MFN fallback",
        "source_class": "mfn",
        "source_url": "https://mfn.se/cis/a/eql-pharma/bokslutskommunike-april-2025-mars-2026-cd65bce1",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2026,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "mfn-fallback-kvartalsrapport-q4-2026",
            "title": "Kvartalsrapport Q4 2026",
            "source": "MFN fallback",
            "source_class": "mfn",
            "source_url": "https://mb.cision.com/Main/11664/4346191/4083691.pdf",
            "date": "2026-05-08",
            "period": "2026-q4",
            "form_type": "year-end-report",
            "report_key": "2026:q4",
            "filename": "4083691.pdf",
            "text_chars": 41933,
            "sha256": "243bec63f15471136e369b234f362772ed692471915062c0de56f5f1daf47455",
            "url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026",
            "txt_url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/part-001.html",
                "chars": 41933
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-02-03",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Delårsrapport April - december 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbe946ee124582ac108ed3da98d82996c&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a951a3c44992327bb2db77496fad2b858",
            "date": "2026-02-03",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "02035276.pdf",
            "text_chars": 42371,
            "sha256": "52422a673f021a36691639ade9117fa61ea8a8a88ba33670de0bfd53b34b609c",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 42371
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2025-07-25",
        "title": "Årsredovisning 2025",
        "original_title": "EQL Pharma Årsredovisning 2024/2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd91c525727fc0df0295d99befb524417&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a69387fbe38be4ed925cc34eb4f8b431e",
            "date": "2025-07-25",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "07243617.pdf",
            "text_chars": 268324,
            "sha256": "2041a192e045b1c51e308ed275f077ecb0a7b85b817d27175b61061e16060ea7",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 176774
              },
              {
                "number": 2,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 91548
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-05-08",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Bokslutskommuniké april 2025 - mars 2026",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b373d1ef2ff828bdf3c827517620fca18&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a6e7ef5729043f29a241ad7d874d6e332",
            "date": "2026-05-08",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "05070091.pdf",
            "text_chars": 41933,
            "sha256": "243bec63f15471136e369b234f362772ed692471915062c0de56f5f1daf47455",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 41933
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-08-08",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Interim Report April - June 2025",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b84fd29d70f23162925698c018f18538f&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ab1555ee131c9a3524768cebab0234307",
            "date": "2025-08-08",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "08078305.pdf",
            "text_chars": 40050,
            "sha256": "e9144e3fb9d5c88ba59507b120d14abfad58884f283d9a57b055484a0b3abb39",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 40050
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-11-05",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Halvårsrapport April - september 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b551840162d2f2fb02f90ddfb404de32d&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a4170b2c5e7518f33330fe90c4bf9e7a3",
            "date": "2025-11-05",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "11044974.pdf",
            "text_chars": 48714,
            "sha256": "a03a4624f6bc622347d76c62bd8885b999eb9fe1f5ddf3b6f0ad7fcee82b230b",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 48714
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-02-05",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Delårsrapport April - december 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b189d065478acd84326e7dd4525a4b538&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aa2d7acdd1c8ac2d3da6749e231f2364f",
            "date": "2025-02-05",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "02041667.pdf",
            "text_chars": 42822,
            "sha256": "e9b7efd792d9f911a366e1328b400f5c7fa42b22ba5d5849f8b6f2af1d93d358",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 42822
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-05-08",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Bokslutskommuniké April 2024 - Mars 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b33f1714716c3ecac1a2d196442217fac&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a1c2d5614926c2f3a4b7a6449e356924e",
            "date": "2025-05-08",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "05078976.pdf",
            "text_chars": 45447,
            "sha256": "5064cd8e9d54e23a20f7172bb0eb219d00f48d953223dc8841a4d9df4e5f873f",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 45447
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-08-08",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Interim Report April - June 2024",
        "category": "Interim report (Q1 and Q3)",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b00bc27f31921715c1f87439b8ab2c90f&lang=en&src=listed",
        "language": "en",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a0a466069e69b7389d170f4dbd2a6c050",
            "date": "2024-08-08",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "08072800.pdf",
            "text_chars": 37269,
            "sha256": "088da055ed4b7355274205a6d0bbae3314c35955cc4561f42f7607f4e3e34b0e",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 37269
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-11-06",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Halvårsrapport april - september 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba6acb8a9725523ec3eead0bd810d0fae&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a491e4fc30d35b04dbb16ea9d2080b8a4",
            "date": "2024-11-06",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "11052871.pdf",
            "text_chars": 43765,
            "sha256": "d3a67c0326bd38a098dbc62a0ecab4df948b6a6769b3c8efa922fe6aab299fc5",
            "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 43765
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 11,
  "nasdaq_report_count": 10,
  "mfn_fallback_count": 1,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "EQL Pharma",
    "identity": {
      "issuer": "XSpray Pharma AB (publ)",
      "lei": "549300NGRQCNZ3X4L157",
      "source": "FI insynsregister",
      "row_count": 49,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "EQL Pharma",
      "query": "XSpray Pharma AB (publ)",
      "candidate_count": 346
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T03:29:50Z",
    "insider": {
      "transactions": 49,
      "all_export_rows": 49,
      "acquisitions": 13,
      "disposals": 8,
      "other": 28,
      "acquisition_value_sek": 8854879.37,
      "disposal_value_sek": 1395041.37,
      "characters": {
        "Avyttring": 8,
        "Förvärv": 13,
        "Lösen minskning": 4,
        "Teckning": 22,
        "Tilldelning": 2
      }
    },
    "short_selling": {
      "aggregate_percent": 1.08,
      "current_public_positions": 0,
      "historical_changes": 0,
      "current_position_sum_over_0_5": 0
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX5398996",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/eql?id=TX5398996"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "EQL Pharma",
      "expected_name": "EQL Pharma",
      "match_score": 100.0,
      "slug": "eql-pharma",
      "url": "https://mfn.se/all/a/eql-pharma",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Läkemedel & Handel",
        "website": "https://mb.cision.com/Main/11664/4377852/4203751.pdf"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX5398996",
      "asset_class": "SHARES",
      "isin": "SE0005497732",
      "symbol": "EQL",
      "company": "EQL Pharma",
      "market": null,
      "last_sale_price": "SEK 21.70",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "XSpray Pharma AB (publ)",
      "lei": "549300NGRQCNZ3X4L157",
      "source": "FI insynsregister",
      "row_count": 49,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "EQL Pharma",
      "query": "XSpray Pharma AB (publ)",
      "candidate_count": 346
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2026",
      "title": "Årsredovisning 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a76a4c5117e3991ffc7424168f48001fe",
      "date": "2026-07-24",
      "period": "2026-annual",
      "form_type": "annual-report",
      "report_key": "2026:annual",
      "filename": "07231483.pdf",
      "text_chars": 270184,
      "sha256": "703dc9cf331cb86c3e871eef359c8c9e1f350bd66693297339ebc43f54cfbb50",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/part-001.html",
          "chars": 177508
        },
        {
          "number": 2,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2026/part-002.html",
          "chars": 92674
        }
      ]
    },
    {
      "doc_id": "mfn-fallback-kvartalsrapport-q4-2026",
      "title": "Kvartalsrapport Q4 2026",
      "source": "MFN fallback",
      "source_class": "mfn",
      "source_url": "https://mb.cision.com/Main/11664/4346191/4083691.pdf",
      "date": "2026-05-08",
      "period": "2026-q4",
      "form_type": "year-end-report",
      "report_key": "2026:q4",
      "filename": "4083691.pdf",
      "text_chars": 41933,
      "sha256": "243bec63f15471136e369b234f362772ed692471915062c0de56f5f1daf47455",
      "url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026",
      "txt_url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/mfn-fallback-kvartalsrapport-q4-2026/part-001.html",
          "chars": 41933
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a6e7ef5729043f29a241ad7d874d6e332",
      "date": "2026-05-08",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "05070091.pdf",
      "text_chars": 41933,
      "sha256": "243bec63f15471136e369b234f362772ed692471915062c0de56f5f1daf47455",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 41933
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a951a3c44992327bb2db77496fad2b858",
      "date": "2026-02-03",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "02035276.pdf",
      "text_chars": 42371,
      "sha256": "52422a673f021a36691639ade9117fa61ea8a8a88ba33670de0bfd53b34b609c",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 42371
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a4170b2c5e7518f33330fe90c4bf9e7a3",
      "date": "2025-11-05",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "11044974.pdf",
      "text_chars": 48714,
      "sha256": "a03a4624f6bc622347d76c62bd8885b999eb9fe1f5ddf3b6f0ad7fcee82b230b",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 48714
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ab1555ee131c9a3524768cebab0234307",
      "date": "2025-08-08",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "08078305.pdf",
      "text_chars": 40050,
      "sha256": "e9144e3fb9d5c88ba59507b120d14abfad58884f283d9a57b055484a0b3abb39",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 40050
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a69387fbe38be4ed925cc34eb4f8b431e",
      "date": "2025-07-25",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "07243617.pdf",
      "text_chars": 268324,
      "sha256": "2041a192e045b1c51e308ed275f077ecb0a7b85b817d27175b61061e16060ea7",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 176774
        },
        {
          "number": 2,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 91548
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a1c2d5614926c2f3a4b7a6449e356924e",
      "date": "2025-05-08",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "05078976.pdf",
      "text_chars": 45447,
      "sha256": "5064cd8e9d54e23a20f7172bb0eb219d00f48d953223dc8841a4d9df4e5f873f",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 45447
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aa2d7acdd1c8ac2d3da6749e231f2364f",
      "date": "2025-02-05",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "02041667.pdf",
      "text_chars": 42822,
      "sha256": "e9b7efd792d9f911a366e1328b400f5c7fa42b22ba5d5849f8b6f2af1d93d358",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 42822
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a491e4fc30d35b04dbb16ea9d2080b8a4",
      "date": "2024-11-06",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "11052871.pdf",
      "text_chars": 43765,
      "sha256": "d3a67c0326bd38a098dbc62a0ecab4df948b6a6769b3c8efa922fe6aab299fc5",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 43765
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a0a466069e69b7389d170f4dbd2a6c050",
      "date": "2024-08-08",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "08072800.pdf",
      "text_chars": 37269,
      "sha256": "088da055ed4b7355274205a6d0bbae3314c35955cc4561f42f7607f4e3e34b0e",
      "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 37269
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/eql-pharma",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 12679,
      "sha256": "754ee727fee795b2c12d399daef367b2e8a20783d1169e760afa0f9358370eec",
      "url": "/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/eql-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 12679
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/eql-pharma/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/eql-pharma/market/history.json",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/eql-pharma/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/eql-pharma/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/eql-pharma/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/eql-pharma/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/eql-pharma/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/eql-pharma/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/eql-pharma/finansinspektionen",
    "transaction_count": 49,
    "aggregate_short_percent": 1.08,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/eql-pharma/llms.txt",
  "json_url": "/company/eql-pharma/company.json",
  "document_index_url": "/company/eql-pharma/documents.json",
  "absolute_url": "https://spela.port0.org/company/eql-pharma"
}